Study Title

Study on the Use of 68Ga-EVG321 for Diagnosing Small Cell Lung Cancer in Patients

Study Details

Description:

The trial aims to compare the imaging results with traditional methods of diagnosing SCLC to see if 68Ga-EVG321 can provide more accurate information about the presence of cancer. By doing so, the study hopes to improve the understanding of how this diagnostic tool can be used in the future to help detect and manage Small Cell Lung Cancer more effectively.

Sponsor:

Evergreen Theragnostics, Inc.

Government Study Link:

EuropeNotInCTCdotGov - Click here to see study on

ClinicalTrials.gov

Drug Details

68Ga-EVG321
Isotope(s):
    GALLIUM-68
    Radioisotope: Ga-68
    Theranostic Role: PET Imaging
    T1/2 (Half-Life): 68 minutes
    Decay Mode: POSITRON β+ (88.9%), GAMMA, ELECTRON CAPTURE (8.7%)
    Energy: Beta: max 1.9 MeV Gamma 1.1 MeV, 511 keV
    Range: N/A
    Decay Daughters: Zn68 (Stable)
    Status: FDA Approvals: NETSPOT® (2016), LOCAMETZ® (2022), ILLUCIX® (2021)
  • GALLIUM-68
Target(s):
  • Cholecystokinin-2 (CCK2R)

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468